Insulet · ISIN: US45784P1012

Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2025 on August 7, 2025, before the opening of the financial markets. In connection with the release, management will host...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 08.07.2025 | 12:00
08 July 2025 12:00PM
Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2025 on August 7, 2025, before the opening of the financial markets. In connection with the release, management will host...
Insulet
© BusinessWire
19 June 2025 12:00PM
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 85th Scientific Sessions taking place June 20 – 23, 2025 at the McCormick Place Convention Center in Chicago, I...
Insulet
© BusinessWire
10 June 2025 02:30PM
Insulet’s Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users
Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod® 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM) System. With this latest integration, the Omnipod 5 Automated Insulin Delivery (AID) System combines the benefits of tubeless...
Insulet
© BusinessWire
23 May 2025 12:01PM
Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami on Tuesday, June 10, 2025 at 9:20 a.m. (Eastern Time). To listen to the live audio webcast...
Insulet
© BusinessWire
13 May 2025 12:00PM
Insulet Announces Publication of 2024 Sustainability Report
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, is proud to announce the publication of its 2024 Sustainability Report. This report underscores Insulet's unwavering commitment to sustainable practices and highlights significant achievements in e...
Insulet
© BusinessWire
08 May 2025 10:01PM
Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025. “Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expan...
Insulet
© BusinessWire
28 April 2025 12:00PM
Insulet Appoints Ashley McEvoy President and CEO
Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Ms. McEvoy succeeds Jim...
Insulet
© BusinessWire
07 April 2025 01:07PM
Insulet Launches Omnipod® 5 Automated Insulin Delivery System in Canada, a Revolutionary New Technology for People Living with Type 1 Diabetes Ages Two Years and Above
New Diabetes Canada Guidelines1 recommend people with type 1 diabetes use an Automated Insulin Delivery System (AID) System for diabetes managementApproximately 300,000 Canadians have type 1 diabetes, with the number of cases growing at an estimated 4.4% per year2The Omnipod 5 System is designed to be customer-centric and aims to deliver exceptio...
Insulet
© PR Newswire
03 April 2025 12:00PM
Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2025 on May 8, 2025, after the close of the financial markets. In connection with the release, management will host a...
Insulet
© BusinessWire
19 March 2025 09:01PM
Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today shared new Omnipod 5 clinical data from its RADIANT study. Results from this multinational randomized controlled trial were presented at the 18th International Conference on Advanced Technolo...
Insulet
© BusinessWire
18 March 2025 09:32PM
Insulet Announces Pricing of Senior Notes Due 2033
Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has priced a private placement of $450 million aggregate principal amount of senior unsecured notes due 2033 (the “Notes”). The Notes will bear interest at an annual rate of 6.50% and will matu...
Insulet
© BusinessWire
18 March 2025 12:35PM
Insulet Announces Proposed Financing Transactions
Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of senior unsecured notes due 2033 (the “Notes”) in a private placement....
Insulet
© BusinessWire
18 March 2025 11:05AM
Insulet Expands Omnipod® 5 to Four More International Markets
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its revolutionary Omnipod 5 Automated Insulin Delivery (AID) System is now available in Australia and will soon be offered in three additional countries, helping transform the lives...
Insulet
© BusinessWire
18 March 2025 11:00AM
From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Company will present results from its multinational Randomized Controlled Trial to Demonstrate the Efficacy of Omnipod 5 Compared with Multiple Daily Injections for Treatment of...
Insulet
© BusinessWire
11 March 2025 11:00AM
Insulet to Host Investor Day on June 5, 2025
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the E...
Insulet
© BusinessWire
20 February 2025 10:01PM
Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2024. "We concluded an incredible year with a very strong fourth quarter, achieving significant milestones a...
Insulet
© BusinessWire
13 January 2025 10:01PM
Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery System is now commercially available in five more countries—Italy, Denmark, Finland, Norway, and Sweden. Omnipod 5 is now available with b...
Insulet
© BusinessWire
10 January 2025 12:00PM
Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, m...
Insulet
© BusinessWire
04 December 2024 10:28PM
Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that it has successfully defended its intellectual property against EOFlow Co., Ltd. (“EOFlow") in federal court. After a four-week trial in the U.S. District Court for the District of...
Insulet
© BusinessWire
20 November 2024 02:30PM
Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott’s FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipo...
Insulet
© BusinessWire
15 November 2024 12:00PM
Insulet to Present at Upcoming Investor Conferences
Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time): The 6th Annual Wolfe Research Healthcare Conference in New York City on Wednesday, November 20, 2024 at 1...
Insulet
© BusinessWire
07 November 2024 10:01PM
Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended September 30, 2024. “We continue to achieve significant milestones and robust revenue growth," said Jim Hollingshead, President and Chi...
Insulet
© BusinessWire
01 November 2024 11:00AM
Insulet Announces Array of Activities to Support National Diabetes Awareness Month and World Diabetes Day in November  
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to recognize National Diabetes Awareness Month and World Diabetes Day with a series of activities in November. “People with diabetes must make dozens of decisions every day t...
Insulet
© BusinessWire
29 October 2024 09:01PM
Omnipod® 5 App for iPhone® Now Fully Available in the United States
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the full market release of the Omnipod 5 App for iPhone® in the U.S. Now available to download for free on the Apple App Store, the App allows users to fully control their Omnipod...
Insulet
© BusinessWire
10 October 2024 03:00PM
National Campaign Launches to Combat Diabetes Stigma Using Comedy
SAN FRANCISCO, Oct. 10, 2024 /PRNewswire/ -- The Spoonful of Laughter campaign is a national initiative using comedy to educate about diabetes, counter harmful stereotypes and stigma, and amplify authentic, respectful, and empowering representations of people living with diabetes.   The Spoonful of Laughter campaign is...
Insulet
© PR Newswire
30 September 2024 12:00PM
Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2024 on November 7, 2024 after the close of the financial markets. In connection with the release, management will ho...
Insulet
© BusinessWire
26 August 2024 10:20PM
Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its groundbreaking Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now indicated for use by people with type 2 diabetes (ages 18 years and older) in the U.S., making it t...
Insulet
© BusinessWire
20 August 2024 12:00PM
Insulet to Present at Upcoming Investor Conferences
Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time): The 2024 Wells Fargo Healthcare Conference in Boston on Wednesday, September 4, 2024 at 9:30 a.m. The...
Insulet
© BusinessWire
14 August 2024 09:00AM
Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted a grand opening celebration at its new manufacturing facility in Johor Bahru, Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.co...
Insulet
© BusinessWire
08 August 2024 10:01PM
Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2024. Second Quarter Financial Highlights: Second quarter 2024 revenue of $488.5 million, up 23.2%, or 23.4% in constant c...
Insulet
© BusinessWire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.